Section 04 · Precursor comparison
NMN vs NR: Comparing the Two Most-Studied NAD+ Precursors
Why most oral NAD+ products are precursors at all, how NMN and NR enter the salvage pathway, and what each has actually been measured to do in human trials.
In plain English
This page compares NMN vs NR — the two building blocks people take by mouth to raise NAD+ (a helper molecule cells use for energy). Both are members of the vitamin-B3 family, and the body turns both into NAD+ through a recycling route called the salvage pathway. Plain "NAD+" capsules are mostly avoided because the NAD+ molecule is too large to absorb well by mouth, so products supply a precursor instead. In randomized human studies, NR raised NAD+ in the blood by as much as 142%, and NMN improved how muscle responds to insulin. Neither is a drug, and nothing here is a dosing instruction — it is a cited summary of what the trials measured.
Why Most Oral Products Are NAD+ Precursors
Plain oral NAD+ is poorly taken up by cells intact, so most experts consider a precursor the rational oral approach — and some argue plain "NAD+" capsules are largely ineffective [12]. A precursor is a building block the body converts into NAD+ through the salvage pathway. The two best-studied are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), both vitamin-B3-family molecules. Niacin (nicotinic acid) feeds the separate Preiss-Handler route [5].
The practical consequence is that almost every randomized "NAD+" trial is really a precursor trial: NR or NMN was given, and whole-blood NAD+ was the readout [4][3]. That is why this digest is careful never to describe an oral-NMN or oral-NR study as "taking NAD+."
Nicotinamide Mononucleotide (NMN) as an NAD+ Precursor
Nicotinamide mononucleotide (NMN) sits one biochemical step from NAD+: NAMPT makes NMN from nicotinamide, and NMNAT converts NMN to NAD+ [5]. In human trials, NMN raised blood NAD+ dose-dependently and produced specific functional readouts. NMN 250 mg/day for 10 weeks improved muscle insulin sensitivity in prediabetic women [1]; NMN 250 mg/day for 12 weeks raised ventilatory thresholds in runners [7]; and a multicenter trial (300/600/900 mg/day) raised blood NAD+ across all doses, naming 600 mg/day optimal [3].
NMN's regulatory status is contested in the United States. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug — a marketplace dispute over supplement status, not a finding that NMN is unsafe or "banned" [12].
Nicotinamide Riboside (NR) as an NAD+ Precursor
Nicotinamide riboside (NR) enters one step upstream of NMN: NRK kinases convert NR to NMN, which then becomes NAD+ [5]. NR is the most clinically studied oral NAD+ booster. At 100/300/1000 mg/day for 8 weeks it raised whole-blood NAD+ by 22%/51%/142% in healthy overweight adults, with no flushing, no LDL-cholesterol elevation, and no significant adverse-event difference from placebo at any dose [4]. NR has also been tested at up to 3000 mg/day in Parkinson's-disease safety research (NR-SAFE) [4]. Its dose-scalable, well-tolerated NAD+ elevation is the clearest demonstration that an oral precursor can move the coenzyme.
Unlike NMN, NR's status as a dietary supplement in the United States is not contested in the same way — the marketplace dispute over supplement status applies specifically to NMN [12]. On the evidence side, NR's advantage is the cleanliness of its dose-response data [4]; NMN's distinguishing data are the functional endpoints, particularly the muscle insulin-sensitivity result [1] and the aerobic-capacity result [7]. Neither precursor has demonstrated a hard clinical outcome in humans, which is the boundary that applies to both [12].
Head to Head: What Differs and What Doesn't
Both NMN and NR reliably raise whole-blood NAD+ in randomized human trials, and both were well tolerated at the doses tested [4][3][1]. The differences are at the margins. NR enters the salvage route one step earlier, via NRK kinases [5]; NMN sits one step from NAD+, converted by NMNAT [5]. NR carries the most systematic dose-response dataset [4]; NMN carries the strongest functional-endpoint readouts in metabolism and exercise [1][7]. NR's supplement status is comparatively settled in the US, while NMN's is under active FDA challenge [12].
What the two share is more important than what separates them. Neither has been shown to prevent disease or extend healthy lifespan in people, and the 2025 Nature Metabolism review concluded human efficacy on hard endpoints remains limited for NAD+ precursors as a class [12]. The honest summary is that both move the biomarker; neither has yet moved a clinical outcome in a controlled human trial.
Is NMN the Same as NAD+?
No. NMN is a precursor; NAD+ is the coenzyme it becomes. NMN is one enzymatic step away — NMNAT converts NMN to NAD+ [5]. The reason the distinction is practical, not pedantic, is bioavailability: oral NAD+ is poorly absorbed intact, while oral NMN is absorbed and reliably raises blood NAD+ [3][12]. So "taking NMN" and "taking NAD+" are not interchangeable, and a trial of one is not evidence for the other [4][3].
Is NAD just vitamin B3?
Not quite. NAD+ is built from vitamin-B3-family precursors — niacin, nicotinamide and nicotinamide riboside — but NAD+ itself is a large dinucleotide coenzyme (663.43 Da), not a vitamin [5]. The B3-related molecules people take to raise NAD+ are the precursors NR and NMN, which the body assembles into the coenzyme through the salvage and NRK routes [5].